EP0818459B1 - Carbohydrate derivatives - Google Patents
Carbohydrate derivatives Download PDFInfo
- Publication number
- EP0818459B1 EP0818459B1 EP97201332A EP97201332A EP0818459B1 EP 0818459 B1 EP0818459 B1 EP 0818459B1 EP 97201332 A EP97201332 A EP 97201332A EP 97201332 A EP97201332 A EP 97201332A EP 0818459 B1 EP0818459 B1 EP 0818459B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- mixture
- carbohydrate derivative
- water
- preparation
- oso
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 CCC(C1)O[C@@](C)C(*)[N+]1[O-] Chemical compound CCC(C1)O[C@@](C)C(*)[N+]1[O-] 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the invention relates to a carbohydrate derivative having antithrombotic activity, a pharmaceutical composition containing the same, as well as the use of said carbohydrate derivative for the manufacture of a medicament.
- Carbohydrate derivatives having antithrombotic activity are known, for example the sulfated glycosaminoglycan derivatives disclosed in EP 84,999. Other sulfated glycosaminoglycan-related carbohydrate derivatives are disclosed in EP 529,715, having improved pharmacological properties. These carbohydrate derivatives are devoid of the characteristic functional groups of glycosaminoglycans, being free hydroxyl groups, N-sulfate and N-acetyl groups.
- Factor Xa plays an important role in the blood coagulation cascade. It catalyzes the formation of thrombin which regulates the last step in the coagulation cascade.
- the prime function of thrombin is the cleavage of fibrinogen to generate fibrin monomers, which form an insoluble gel, a fibrin clot, by cross-linking.
- the compounds of the present invention are useful for treating and preventing thrombin-mediated and thrombin-associated diseases.
- This includes a number of thrombotic and prothrombotic states in which the coagulation cascade is activated which include, but are not limited to, deep vein thrombosis, pulmonary embolism, thrombophlebitis, arterial occlusion from thrombosis or embolism, arterial reocclusion during or after angioplasty or thrombolysis, restenosis following arterial injury or invasive cardiological procedures, postoperative venous thrombosis or embolism, acute or chronic atherosclerosis, stroke, myocardial infarction, cancer and metastasis, and neurodegenerative diseases.
- the carbohydrate derivatives of the invention may also be used as inhibitors of smooth muscle cell proliferation and for the treatment of angiogenesis, cancer and retrovirus infections, like HIV. Further, the compounds of the invention may be used as anticoagulants and anticoagulant coatings in extracorporeal blood circuits, as necessary in dialysis and surgery. The compounds of the invention may also be used as in vitro or ex vivo anticoagulants.
- Preferred carbohydrate derivatives according to the invention have the formula I, wherein R 2 is (1-6C)alkyl, R 3 is SO 3 - , R 4 is OSO 3 - , and R 1 , n and p are as previously defined; or a pharmaceutically acceptable salt thereof
- carbohydrate derivatives have formula I wherein R 2 is methyl. Particularly preferred carbohydrate derivatives have formula I, wherein n is 1 and p is 1. Most preferred are carbohydrate derivatives of formula I, wherein R 1 is CH 2 OSO 3 -
- (1-6C)alkyl means a branched or unbranched alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, isopropyl, t-butyl, isopentyl, hexyl, and the like.
- Preferred alkyl groups are (1-4C)alkyl groups, such as methyl, ethyl, (iso)propyl, n-butyl and t-butyl.
- the most preferred alkyl group is methyl.
- the counter-ions which compensate the charged moieties are pharmaceutically acceptable counter-ions, like hydrogen, or more preferably alkali or earth-alkali metal ions, like sodium, calcium, or magnesium.
- the carbohydrate derivatives according to this invention may be prepared by coupling of a protected glycerol-like or glycol-like moiety to the 4-hydroxy group of the non-reducing end of a further protected tetrasaccharide, which may be produced according to the method described by Westerduin P., Bioorg. and Med. Chem., 2, 1267-1280, 1994.
- the protecting groups are removed, followed by sulfation of the compound, resulting in a carbohydrate derivative of formula I.
- the compounds of the invention may be administered enterally or parenterally, and for humans preferably in a daily dosage of 0,001-10 mg per kg body weight.
- the compounds, when orally, buccally or sublingually active may be compressed into solid dosage units, such as pills, tablets, or be processed into capsules or suppositories.
- the compounds can also be applied as an injection preparation in the form of a solution, suspension, emulsion, or as a spray, e.g. a nasal spray.
- a spray e.g. a nasal spray.
- dosage units e.g. tablets
- conventional additives such as fillers, colorants, polymeric binders and the like is contemplated.
- any pharmaceutically acceptable additive which does not interfere with the function of the active compounds can be used.
- Suitable carriers with which the compositions can be administered include lactose, starch, cellulose derivatives and the like, or mixtures thereof, used in suitable amounts.
- Methyl sulfide (1.45 ml) was added to a solution of 10 (600 mg) in acetonitrile:dichloromethane (1:1, v/v; 8 ml). The reaction mixture was cooled to 0°C and a mixture of dry benzoylperoxide (3.63 g) in acetonitrile:dichloromethane (1:1, v/v; 10 ml) was added dropwise. After stirring for 16 h at 20 °C the mixture was diluted with dichloromethane and washed with aqueous sodium hydrogen carbonate and water. The organic layer was dried over magnesium sulfate and concentrated in vacuo. After purification by silica gel column chromatography 400 mg of 11 was isolated.
- Compound 12 was prepared analogously to the procedures described by P. Westerduin et al. Bioorganic and Medicinal Chemistry 1994, vol 2, no. 11, pp. 1267-1280. During the reaction steps to afford 12 the uronic acids were protected by benzyl groups instead of methyl groups.
- Compound 13 was prepared in a manner similar as described for compound 4 by coupling compound 11 to compound 12.
Description
- The invention relates to a carbohydrate derivative having antithrombotic activity, a pharmaceutical composition containing the same, as well as the use of said carbohydrate derivative for the manufacture of a medicament.
- Carbohydrate derivatives having antithrombotic activity are known, for example the sulfated glycosaminoglycan derivatives disclosed in EP 84,999. Other sulfated glycosaminoglycan-related carbohydrate derivatives are disclosed in EP 529,715, having improved pharmacological properties. These carbohydrate derivatives are devoid of the characteristic functional groups of glycosaminoglycans, being free hydroxyl groups, N-sulfate and N-acetyl groups.
- It has now been found that the carbohydrate derivatives of this invention having the formula I, wherein R1 is H or CH2OSO3 -; R2 and R3 are independently H, (1-6C)alkyl or SO3 - ; R4 is OSO3 - or NHSO3 -; n is 0 or 1; p is 1 or 2; or a pharmaceutically acceptable salt thereof, have an anti-Xa activity which is substantially higher than that of saccharides not having the glycerol-like or glycol-like group at the 4-position of the non-reducing end.
- Factor Xa plays an important role in the blood coagulation cascade. It catalyzes the formation of thrombin which regulates the last step in the coagulation cascade. The prime function of thrombin is the cleavage of fibrinogen to generate fibrin monomers, which form an insoluble gel, a fibrin clot, by cross-linking.
- The compounds of the present invention are useful for treating and preventing thrombin-mediated and thrombin-associated diseases. This includes a number of thrombotic and prothrombotic states in which the coagulation cascade is activated which include, but are not limited to, deep vein thrombosis, pulmonary embolism, thrombophlebitis, arterial occlusion from thrombosis or embolism, arterial reocclusion during or after angioplasty or thrombolysis, restenosis following arterial injury or invasive cardiological procedures, postoperative venous thrombosis or embolism, acute or chronic atherosclerosis, stroke, myocardial infarction, cancer and metastasis, and neurodegenerative diseases. The carbohydrate derivatives of the invention may also be used as inhibitors of smooth muscle cell proliferation and for the treatment of angiogenesis, cancer and retrovirus infections, like HIV.
Further, the compounds of the invention may be used as anticoagulants and anticoagulant coatings in extracorporeal blood circuits, as necessary in dialysis and surgery. The compounds of the invention may also be used as in vitro or ex vivo anticoagulants. - Preferred carbohydrate derivatives according to the invention have the formula I, wherein R2 is (1-6C)alkyl, R3 is SO3 -, R4 is OSO3 -, and R1, n and p are as previously defined; or a pharmaceutically acceptable salt thereof
- More preferred carbohydrate derivatives have formula I wherein R2 is methyl. Particularly preferred carbohydrate derivatives have formula I, wherein n is 1 and p is 1. Most preferred are carbohydrate derivatives of formula I, wherein R1 is CH2OSO3 -
- The term (1-6C)alkyl means a branched or unbranched alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, isopropyl, t-butyl, isopentyl, hexyl, and the like. Preferred alkyl groups are (1-4C)alkyl groups, such as methyl, ethyl, (iso)propyl, n-butyl and t-butyl. The most preferred alkyl group is methyl.
- The counter-ions which compensate the charged moieties are pharmaceutically acceptable counter-ions, like hydrogen, or more preferably alkali or earth-alkali metal ions, like sodium, calcium, or magnesium.
- The carbohydrate derivatives according to this invention may be prepared by coupling of a protected glycerol-like or glycol-like moiety to the 4-hydroxy group of the non-reducing end of a further protected tetrasaccharide, which may be produced according to the method described by Westerduin P., Bioorg. and Med. Chem., 2, 1267-1280, 1994. Hereafter, the protecting groups are removed, followed by sulfation of the compound, resulting in a carbohydrate derivative of formula I.
- For the treatment of venous thrombosis or for the inhibition of smooth muscle cell proliferation the compounds of the invention may be administered enterally or parenterally, and for humans preferably in a daily dosage of 0,001-10 mg per kg body weight. Mixed with pharmaceutically suitable auxiliaries, e.g. as described in the standard reference, Gennaro et al., Remington's Pharmaceutical Sciences, (18th ed., Mack Publishing Company, 1990, see especially Part 8: Pharmaceutical Preparations and Their Manufacture), the compounds, when orally, buccally or sublingually active, may be compressed into solid dosage units, such as pills, tablets, or be processed into capsules or suppositories. By means of pharmaceutically suitable liquids the compounds can also be applied as an injection preparation in the form of a solution, suspension, emulsion, or as a spray, e.g. a nasal spray.
For making dosage units, e.g. tablets, the use of conventional additives such as fillers, colorants, polymeric binders and the like is contemplated. In general any pharmaceutically acceptable additive which does not interfere with the function of the active compounds can be used.
Suitable carriers with which the compositions can be administered include lactose, starch, cellulose derivatives and the like, or mixtures thereof, used in suitable amounts. - The invention is further illustrated by the following examples.
- (In the examples reference is made to
flow sheets - To a cooled (0°C) solution of 2-benzyloxyethanol 1 (2.84 ml) and chloromethyl methyl sulfide (1.59 ml) in ethylene glycol dimethyl ether (25 ml) was added sodium hydride, 60% dispersion in mineral oil (1.2 g) under nitrogen atmosphere and the mixture was stirred for 20 h at room temperature. Methanol was added to the reaction mixture and stirring was continued for 15 min. The mixture was diluted with ethyl acetate (100 ml), subsequently washed with aqueous sodium hydrogen carbonate and water and the organic layer was dried over magnesium sulfate and concentrated in vacuo. The crude product was purified by silica gel column chromatography to give 2.5 g of 2.
- The synthesis of 3 has been described in Bioorganic and Medicinal Chemistry,
vol 2, no. 11, pp 1267-1280, 1994 (P. Westerduin et al.). - A mixture of 3 (125 mg), 2 (64 mg) and powdered molecular sieves (4Å) in dichloromethane (1.5 ml) was stirred under a nitrogen atmosphere for 15 min. The solution was cooled (5°C) and a freshly prepared solution containing N-iodosuccinimide (68 mg) and trifluoromethanesulphonic acid (2.7µl) in 1.5 ml of 1,2-dichloroethane - dioxane (1/1, v/v) was introduced. After 10 min the red reaction mixture was filtered, diluted with dichloromethane, washed successively with aqueous sodium thiosulfate and aqueous sodium hydrogen carbonate. The organic layer was dried over magnesium sulfate and concentrated in vacuo. The residue was purified by size exclusion chromatography on a Sephadex LH-20 suspended in dichloromethane-methanol (2/1, v/v) to furnish 108 mg of 4.
- To a cooled (-5°C) solution of 4 (105 mg) in tetrahydrofuran (7.3 ml) a 30% aqueous solution of hydrogen peroxide (3.8 ml) was added and after 10 min stirring a lithium hydroxide solution (1.25 M, 1.7 ml) was added. The mixture was stirred for 2 h at -5°C, after which the temperature was raised to 0°C. After 20 h stirring the temperature was raised to 20°C and stirring was continued for 24 h. The reaction mixture was cooled (0°C), subsequently methanol (7.0 ml) and aqueous sodium hydroxide (4 M, 2.0 ml) were added. After stirring for 1 h the temperature was raised again to 20°C and stirring was continued for another 20 h. The mixture was cooled (0°C), acidified to
pH 3 with hydrochloric acid (2 N) and extracted with dichloromethane.The organic layer was washed with aqueous sodium sulfite (5%), dried over magnesium sulfate and concentrated in vacuo. The crude product was purified by silica gel column chromatography to give 80 mg of 5. - To a solution of 6 (80 mg) in a mixture of water (7 ml) and 2-methyl-2-propanol (7 ml) 80 mg of palladium on charcoal (10 %) was added. The reaction mixture was placed under a hydrogen atmosphere for 16 h. The catalyst was removed by filtration and rinsed with 2-methyl-2-propanol/water mixtures. The filtrate and washings were concentrated in vacuo and lyophilized to give 38 mg of 6.
- A solution of 6 (38 mg) in water (0.8 ml) was eluted with water over a Dowex 50WX8H+ column and the pooled fractions were evaporated to dryness. After evaporation with N,N-dimethylformamide the residue was dissolved in N,N-dimethylformamide (2.5 ml), placed under an nitrogen atmosphere and triethylamine sulfurtrioxide complex (287 mg) was added. The mixture was stirred overnight at 50°C, cooled to 0°C and an aqueous solution of sodium hydrogen carbonate (533 mg) was added. The mixture was stirred for 1 h at 20°C, concentrated to a small volume and desalted on a Sephadex G-25 column suspended in water:acetonitrile 9:1 (v/v). The crude product was eluted on a Dowex 50WX8Na+ column and purified by anion exchange column chromatography (HPLC, Mono-
Q 5/5, sodium chloride gradient) to give 12 mg of 7. {[α]20 D = + 31.1 (c=1; water)} and 18 mg of 8 {[α]20 D = 34.8 (c=0.93; water)}. - A solution of benzoyl chloride (26,3 ml) in dry dioxane (26 ml) was added dropwise during 1 h to a cooled (-20°C) mixture of glycerol (10 g) and pyridine (109 ml). The resulting mixture was stirred for 16 h at 0°C, after which water was added. After 15 min stirring the mixture was concentrated to one fifth of its volume, diluted with dichloromethane and washed with water, aqueous sodium hydrogen carbonate and water. The organic layer was dried over magnesium sulphate and concentrated in vacuo. The resulting oil was purified by silica gel column chromatography to give 21 g of 10.
- Methyl sulfide (1.45 ml) was added to a solution of 10 (600 mg) in acetonitrile:dichloromethane (1:1, v/v; 8 ml). The reaction mixture was cooled to 0°C and a mixture of dry benzoylperoxide (3.63 g) in acetonitrile:dichloromethane (1:1, v/v; 10 ml) was added dropwise. After stirring for 16 h at 20 °C the mixture was diluted with dichloromethane and washed with aqueous sodium hydrogen carbonate and water. The organic layer was dried over magnesium sulfate and concentrated in vacuo. After purification by silica gel column chromatography 400 mg of 11 was isolated.
-
Compound 12 was prepared analogously to the procedures described by P. Westerduin et al. Bioorganic and Medicinal Chemistry 1994,vol 2, no. 11, pp. 1267-1280.
During the reaction steps to afford 12 the uronic acids were protected by benzyl groups instead of methyl groups. -
Compound 13 was prepared in a manner similar as described for compound 4 by couplingcompound 11 to compound 12. - A suspension of sodium hydrogencarbonate (142 mg) in water (2 ml) and Pd/C (400 mg) were added to a solution of 13 (480 mg) in 2-methyl-2-propanol (60 ml). The mixture was placed in an atmosphere of hydrogen for 16 h. The catalyst was removed by filtration and washed with 2-methyl-2-propanol/water mixtures. The combined filtrate and washings were concentrated in vacuo to give 315 mg of 14, which was used without further purification.
- Compound 14 (315 mg) was dissolved in 0.35 N aqueous sodium hydroxide (10 ml). The reaction mixture was stirred overnight after which the pH was adjusted to 8.5 with 1 N hydrochloride acid. The mixture was desalted on a Sephadex G-25 column suspended in a mixture of water:acetonitril:triethylamine 90:10:0.1 (v/v/v). The appropriate fractions were pooled and concentrated in vacuo. The product was again subjected to hydrogenolysis in a similar manner as described for
compound 14. After work up and concentration of the filtrate and washings, the mixture was desalted on Sephadex G-25 column suspended in a mixture of water:acetonitril:triethylamine 90:10:0.1 (v/v/v). The appropriate fractions were pooled, concentrated in vacuo, eluted on a Dowex 50WX8Na+ column with water and finally lyophilised to give 165 mg of 15. - A solution of 15 (165 mg) was evaporated with N,N-dimethylformamide and dissolved in N,N-dimethylformamide (11.0 ml). Triethylamine sulfurtrioxide complex (1.31 g) was added to the reaction mixture. After stirring for 16 h at 50°C, the mixture was cooled (0°C) aqueous sodium hydrogen carbonate (2.43 g) was added and stirring was continued for 1 h at 20°C after which the solution was concentrated in vacuo. The residue was desalted on a Sephadex G-25 column suspended in water-acetonitrile 9:1 (v/v) and the appropriate fractions were pooled and concentrated in vacuo. After elution on a Dowex 50WX8Na+ column the product was purified on a Q-Sepharose High Load column using a sodium chloride gradient, to give 160 mg of 16.
{[α]20 D = +24.0 (c=0.77, H2O)}.
Claims (8)
- The carbohydrate derivative of claim 1 wherein is R2 is (1-6C)alkyl, R3 is SO3 -, R4 is OSO3 -, and R1, n and p are as previously defined.
- The carbohydrate derivative of claim 2, wherein R2 is methyl.
- The carbohydrate derivative of claim 2 or 3, wherein n is 1 and p is 1.
- The carbohydrate derivative of any one of claims 2 - 4, wherein R1 is CH2OSO3 -.
- A pharmaceutical composition comprising the carbohydrate derivative of any one of claims 1-5 and pharmaceutically suitable auxiliaries.
- The carbohydrate derivative of any one of claims 1 - 5 for use in therapy.
- Use of the carbohydrate derivative of any one of claims 1 - 5 for the manufacture of a medicament for treating or preventing thrombosis or inhibiting smooth muscle cell proliferation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97201332A EP0818459B1 (en) | 1996-05-08 | 1997-05-02 | Carbohydrate derivatives |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96201267 | 1996-05-08 | ||
EP96201267 | 1996-05-08 | ||
EP97201332A EP0818459B1 (en) | 1996-05-08 | 1997-05-02 | Carbohydrate derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0818459A2 EP0818459A2 (en) | 1998-01-14 |
EP0818459A3 EP0818459A3 (en) | 1998-04-29 |
EP0818459B1 true EP0818459B1 (en) | 2002-04-03 |
Family
ID=8223964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97201332A Expired - Lifetime EP0818459B1 (en) | 1996-05-08 | 1997-05-02 | Carbohydrate derivatives |
Country Status (27)
Country | Link |
---|---|
US (1) | US5872110A (en) |
EP (1) | EP0818459B1 (en) |
JP (1) | JP4201360B2 (en) |
KR (1) | KR100443802B1 (en) |
CN (1) | CN1115345C (en) |
AR (1) | AR007052A1 (en) |
AT (1) | ATE215547T1 (en) |
AU (1) | AU711630B2 (en) |
BR (1) | BRPI9703099B8 (en) |
CA (1) | CA2204204C (en) |
CZ (1) | CZ292439B6 (en) |
DE (1) | DE69711505T2 (en) |
DK (1) | DK0818459T3 (en) |
ES (1) | ES2176609T3 (en) |
HK (1) | HK1004399A1 (en) |
HU (1) | HU226370B1 (en) |
ID (1) | ID17932A (en) |
IL (1) | IL120722A (en) |
NO (1) | NO308251B1 (en) |
NZ (1) | NZ314745A (en) |
PL (1) | PL183469B1 (en) |
PT (1) | PT818459E (en) |
RU (1) | RU2183638C2 (en) |
SG (2) | SG55310A1 (en) |
TR (1) | TR199700354A2 (en) |
TW (1) | TW498078B (en) |
ZA (1) | ZA973892B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE307596T1 (en) * | 1997-05-27 | 2005-11-15 | Sanofi Aventis | USE OF AN OLIGOSACCHARIDE TO PREVENT BLOOD CLOTTING IN EXTRACORPORAL CIRCUITS |
NZ508623A (en) * | 1998-06-17 | 2002-11-26 | Akzo Nobel Nv | Antithrombotic peptide compounds with saccharide radicals |
CA2377734A1 (en) * | 1999-06-30 | 2001-01-11 | Hamilton Civic Hospitals Research Development, Inc. | Heparin compositions that inhibit clot associated coagulation factors |
AU1594801A (en) * | 1999-11-12 | 2001-06-06 | Emisphere Technologies, Inc. | Liquid heparin formulation |
US8600783B2 (en) * | 2000-08-18 | 2013-12-03 | The Crawford Group, Inc. | Business to business computer system for communicating and processing rental car reservations using web services |
HUP0300939A2 (en) * | 2000-09-08 | 2003-09-29 | Hamilton Civic Hospitals Research Development, Inc. | Antithrombotic compositions |
CN109134555B (en) * | 2017-06-15 | 2021-09-28 | 南京正大天晴制药有限公司 | Anticoagulant pentasaccharide compound and preparation method and medical application thereof |
CN109134554B (en) * | 2017-06-15 | 2021-09-28 | 南京正大天晴制药有限公司 | Anticoagulant pentasaccharide compound and preparation method and medical application thereof |
CN109134553B (en) * | 2017-06-15 | 2021-09-28 | 南京正大天晴制药有限公司 | Anticoagulant pentasaccharide compound and preparation method and medical application thereof |
CN111057115B (en) * | 2019-12-17 | 2022-03-22 | 广东海洋大学 | Antithrombotic heparinoid extracted from Guifei mussel and preparation method and application thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0300099A1 (en) * | 1987-07-20 | 1989-01-25 | Akzo N.V. | New pentasaccharides |
IE64378B1 (en) * | 1990-04-23 | 1995-07-26 | Akzo Nv | Carbohydrate derivatives comprising a trisaccharide unit |
US5378829A (en) * | 1990-04-23 | 1995-01-03 | Akzo N.V. | Sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type |
US5707973A (en) * | 1991-04-23 | 1998-01-13 | Rhone-Poulenc Rorer S.A. | Sulfated polysaccharids for treatment or prevention of thromboses |
IL102758A (en) * | 1991-08-23 | 1997-03-18 | Akzo Nv | Glycosaminoglycanoid derivatives, their preparation and pharmaceutical compositions comprising them |
FR2704226B1 (en) * | 1993-04-22 | 1995-07-21 | Sanofi Elf | 3-DESOXY OLIGOSACCHARIDES, THEIR PREPARATION PROCESSES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
-
1997
- 1997-04-24 IL IL12072297A patent/IL120722A/en not_active IP Right Cessation
- 1997-04-30 US US08/876,107 patent/US5872110A/en not_active Expired - Lifetime
- 1997-05-01 CA CA002204204A patent/CA2204204C/en not_active Expired - Lifetime
- 1997-05-02 ES ES97201332T patent/ES2176609T3/en not_active Expired - Lifetime
- 1997-05-02 DE DE69711505T patent/DE69711505T2/en not_active Expired - Lifetime
- 1997-05-02 EP EP97201332A patent/EP0818459B1/en not_active Expired - Lifetime
- 1997-05-02 AT AT97201332T patent/ATE215547T1/en active
- 1997-05-02 PT PT97201332T patent/PT818459E/en unknown
- 1997-05-02 DK DK97201332T patent/DK0818459T3/en active
- 1997-05-06 NZ NZ314745A patent/NZ314745A/en not_active IP Right Cessation
- 1997-05-06 HU HU9700852A patent/HU226370B1/en unknown
- 1997-05-06 AU AU20086/97A patent/AU711630B2/en not_active Expired
- 1997-05-06 ZA ZA973892A patent/ZA973892B/en unknown
- 1997-05-07 ID IDP971528A patent/ID17932A/en unknown
- 1997-05-07 CN CN97111112A patent/CN1115345C/en not_active Expired - Lifetime
- 1997-05-07 NO NO972120A patent/NO308251B1/en not_active IP Right Cessation
- 1997-05-07 RU RU97107418/04A patent/RU2183638C2/en active
- 1997-05-07 JP JP11685097A patent/JP4201360B2/en not_active Expired - Lifetime
- 1997-05-07 CZ CZ19971386A patent/CZ292439B6/en not_active IP Right Cessation
- 1997-05-07 KR KR1019970017376A patent/KR100443802B1/en not_active IP Right Cessation
- 1997-05-07 SG SG1997001403A patent/SG55310A1/en unknown
- 1997-05-07 PL PL97319843A patent/PL183469B1/en unknown
- 1997-05-08 AR ARP970101915A patent/AR007052A1/en active IP Right Grant
- 1997-05-08 BR BRPI9703099 patent/BRPI9703099B8/en not_active IP Right Cessation
- 1997-05-08 TR TR97/00354A patent/TR199700354A2/en unknown
- 1997-05-19 TW TW086106674A patent/TW498078B/en not_active IP Right Cessation
- 1997-05-27 SG SG1997001743A patent/SG46779A1/en unknown
-
1998
- 1998-05-01 HK HK98103734A patent/HK1004399A1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5543403A (en) | Sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type | |
EP0529715B1 (en) | Sulfated glycosaminoglycanoid derivatives | |
HU215152B (en) | Process for producing carbohydrate derivatives containing pentasaccharide unit and pharmaceutical compositions containing them | |
EP0818459B1 (en) | Carbohydrate derivatives | |
US6528497B1 (en) | Synthetic polysaccharides, their method of production and pharmaceutical compositions containing same | |
EP1032579B1 (en) | Carbohydrate derivatives | |
US5705489A (en) | Bisconjugates comprising two saccharides and a spacer | |
KR100533565B1 (en) | New pentasaccharides, their methods of production and pharmaceutical compositions containing same | |
US5773605A (en) | Sulfated glycosaminoglycanoid derivatives of the heparin sulfate type | |
US20040068108A1 (en) | Synthetic polysaccharides, process for their preparation and pharmaceutical compositions containing them | |
US5529985A (en) | Sulfated glycosaminoglycanoid derivatives of the dermatan sulfate and chondroitin sulfate type | |
MXPA97003365A (en) | Carbohydr derivatives | |
US5668274A (en) | Sulfated glycosaminoglycanoid derivatives of the dermatan sulfate and chondroitin sulfate type | |
EP2721044B1 (en) | Synthetic pentasaccharides having short half-life and high activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RHK1 | Main classification (correction) |
Ipc: C07H 3/06 |
|
17P | Request for examination filed |
Effective date: 19981029 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
17Q | First examination report despatched |
Effective date: 20010411 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
REF | Corresponds to: |
Ref document number: 215547 Country of ref document: AT Date of ref document: 20020415 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: ISLER & PEDRAZZINI AG |
|
REF | Corresponds to: |
Ref document number: 69711505 Country of ref document: DE Date of ref document: 20020508 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: SANOFI-SYNTHELABO Owner name: AKZO NOBEL N.V. |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
ET | Fr: translation filed | ||
NLT2 | Nl: modifications (of names), taken from the european patent patent bulletin |
Owner name: AKZO NOBEL N.V. EN SANOFI-SYNTHELABO |
|
NLXE | Nl: other communications concerning ep-patents (part 3 heading xe) |
Free format text: PAT. BUL. 06/2002: CORR.: AKZO NOBEL N.V. AND SANOFI-SYNTHELABO |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20020514 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20020402038 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2176609 Country of ref document: ES Kind code of ref document: T3 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20030106 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TQ |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PUE Owner name: SANOFI-SYNTHELABO Free format text: AKZO NOBEL N.V.#VELPERWEG 76#6824 BM ARNHEM (NL) $ SANOFI-SYNTHELABO#174, AVENUE DE FRANCE#75013 PARIS (FR) -TRANSFER TO- SANOFI-SYNTHELABO#174, AVENUE DE FRANCE#75013 PARIS (FR) |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: PC4A Free format text: SANOFI-SYNTHELABO FR Effective date: 20040309 |
|
NLS | Nl: assignments of ep-patents |
Owner name: SANOFI-SYNTHELABO |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: SANOFI-AVENTIS Free format text: SANOFI-SYNTHELABO#174, AVENUE DE FRANCE#75013 PARIS (FR) -TRANSFER TO- SANOFI-AVENTIS#174, AVENUE DE FRANCE#75013 PARIS (FR) |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: PD4A Free format text: SANOFI-AVENTIS FR Effective date: 20050126 |
|
NLT1 | Nl: modifications of names registered in virtue of documents presented to the patent office pursuant to art. 16 a, paragraph 1 |
Owner name: SANOFI -AVENTIS |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CD |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCAR Free format text: ISLER & PEDRAZZINI AG;POSTFACH 1772;8027 ZUERICH (CH) |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 69711505 Country of ref document: DE Representative=s name: WUESTHOFF & WUESTHOFF PATENT- UND RECHTSANWAEL, DE |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 69711505 Country of ref document: DE Representative=s name: WUESTHOFF & WUESTHOFF, PATENTANWAELTE PARTG MB, DE Effective date: 20130205 Ref country code: DE Ref legal event code: R082 Ref document number: 69711505 Country of ref document: DE Representative=s name: WUESTHOFF & WUESTHOFF PATENT- UND RECHTSANWAEL, DE Effective date: 20130205 Ref country code: DE Ref legal event code: R081 Ref document number: 69711505 Country of ref document: DE Owner name: SANOFI-AVENTIS, FR Free format text: FORMER OWNER: SANOFI-AVENTIS, PARIS, FR Effective date: 20130205 Ref country code: DE Ref legal event code: R081 Ref document number: 69711505 Country of ref document: DE Owner name: SANOFI, FR Free format text: FORMER OWNER: SANOFI-AVENTIS, PARIS, FR Effective date: 20130205 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MC Payment date: 20160331 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20160427 Year of fee payment: 20 Ref country code: BE Payment date: 20160324 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20160510 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20160509 Year of fee payment: 20 Ref country code: GB Payment date: 20160427 Year of fee payment: 20 Ref country code: ES Payment date: 20160414 Year of fee payment: 20 Ref country code: FI Payment date: 20160509 Year of fee payment: 20 Ref country code: GR Payment date: 20160415 Year of fee payment: 20 Ref country code: CH Payment date: 20160511 Year of fee payment: 20 Ref country code: DE Payment date: 20160426 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20160425 Year of fee payment: 20 Ref country code: IT Payment date: 20160524 Year of fee payment: 20 Ref country code: SE Payment date: 20160511 Year of fee payment: 20 Ref country code: FR Payment date: 20160412 Year of fee payment: 20 Ref country code: PT Payment date: 20160502 Year of fee payment: 20 Ref country code: DK Payment date: 20160510 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69711505 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MK Effective date: 20170501 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EUP Effective date: 20170502 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20170501 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK07 Ref document number: 215547 Country of ref document: AT Kind code of ref document: T Effective date: 20170502 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MK9A |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20170501 Ref country code: IE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20170502 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20170825 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20170511 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20170503 |